###begin article-title 0
APRIL is overexpressed in cancer: link with tumor progression
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
BAFF and APRIL share two receptors - TACI and BCMA - and BAFF binds to a third receptor, BAFF-R. Increased expression of BAFF and APRIL is noted in hematological malignancies. BAFF and APRIL are essential for the survival of normal and malignant B lymphocytes, and altered expression of BAFF or APRIL or of their receptors (BCMA, TACI, or BAFF-R) have been reported in various B-cell malignancies including B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Hodgkin's lymphoma, multiple myeloma, and Waldenstrom's macroglobulinemia.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 30 59 30 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAFF, APRIL, TACI and BAFF-R </italic>
###xml 81 86 <span type="species:ncbi:9606">human</span>
We compared the expression of BAFF, APRIL, TACI and BAFF-R gene expression in 40 human tumor types - brain, epithelial, lymphoid, germ cells - to that of their normal tissue counterparts using publicly available gene expression data, including the Oncomine Cancer Microarray database.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TACI </italic>
###xml 169 184 169 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAFF and APRIL </italic>
###xml 235 241 235 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APRIL </italic>
We found significant overexpression of TACI in multiple myeloma and thyroid carcinoma and an association between TACI expression and prognosis in lymphoma. Furthermore, BAFF and APRIL are overexpressed in many cancers and we show that APRIL expression is associated with tumor progression. We also found overexpression of at least one proteoglycan with heparan sulfate chains (HS), which are coreceptors for APRIL and TACI, in tumors where APRIL is either overexpressed or is a prognostic factor. APRIL could induce survival or proliferation directly through HS proteoglycans.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
Taken together, these data suggest that APRIL is a potential prognostic factor for a large array of malignancies.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 163 164 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 316 317 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 408 409 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 697 698 697 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 699 700 699 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 792 793 792 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 857 859 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 860 862 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
APRIL and BAFF are two members of the TNF family. BAFF is a type II transmembrane protein that can be secreted after proteolytical cleavage from the cell membrane[1,2]. APRIL is processed intracellularly within the Golgi apparatus by a furin pro-protein convertase prior to secretion of the biologically active form[3]. APRIL can also be expressed as a cell surface fusion protein with TWEAK called TWE-PRIL[4,5]. Both ligands bind to TACI (transmembrane activator and CAML interactor) and BCMA (B-cell maturation antigen), two members of the TNFR family. BAFF binds additionally to BAFF receptor (BAFF-R). BAFF is involved in the survival of normal and malignant B cells and normal plasmablasts [6-8]. APRIL is highly expressed in several tumor tissues, stimulates the growth of tumor cells[9] and promotes survival of normal plasmablasts and plasma cells[10,11].
###end p 11
###begin p 12
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 149 151 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
Evidence has been presented that BAFF/APRIL contribute to malignancies of B cells and plasma cells: non-Hodgkin's lymphoma [12-16], Hodgkin lymphoma[17], chronic lymphocytic leukemia[18,19], multiple myeloma [20-24] and Waldenstrom's macroglobulinemia[25].
###end p 12
###begin p 13
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 697 699 697 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1261 1263 1261 1263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1289 1295 1289 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 1390 1392 1390 1392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 537 542 <span type="species:ncbi:9606">human</span>
###xml 554 563 <span type="species:ncbi:10090">nude mice</span>
###xml 614 619 <span type="species:ncbi:9606">human</span>
###xml 658 663 <span type="species:ncbi:9606">human</span>
Recombinant APRIL binds to several cell lines that do not express detectable mRNA for TACI and BCMA and proteoglycans were identified as APRIL-specific binding partners. This binding is mediated by heparan sulfate (HS) side chains and can be inhibited by heparin[26,27]. Binding of APRIL to proteoglycans or BCMA/TACI involves different regions in APRIL. APRIL binds HS proteoglycans via the lysine-rich region in the N-terminal part, leaving the TNF-like region available to interact with others receptors. Blockade of APRIL/BAFF using human BCMA-Ig in nude mice inhibited the growth of a subcutaneously injected human lung carcinoma cell line (A549) and a human colon carcinoma cell line (HT29)[28]. These cell lines express APRIL, but not BAFF, TACI, BCMA or BAFF-R suggesting that HS proteoglycans could mediate the growth response to APRIL. However, BCMA-Fc leaves the APRIL binding HSPG domain intact. This blockade may suggest that the TNF-receptor binding domain is also necessary for activity, and that an additional APRIL-specific receptor might exist. B-cell lymphoma cells can bind large amount of APRIL secreted by neutrophils via proteoglycan binding and the high expression of APRIL in tumor lesion correlates with B-cell lymphoma aggressiveness[16]. More recently, Bischof et al demonstrated that TACI binds also HS proteoglycans like syndecan-1, syndecan-2 and syndecan-4 [29].
###end p 13
###begin p 14
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 262 274 262 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAFF, APRIL </italic>
###xml 299 311 299 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAFF-R, BCMA</italic>
###xml 317 322 317 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TACI </italic>
These data demonstrate that BAFF/APRIL are potent growth factors in B cell malignancies. Furthermore, APRIL could be implicated in tumor emergence and/or progression due to its ability to bind HS proteoglycans [26-28]. Therefore, we looked for the expression of BAFF, APRIL and of their receptors - BAFF-R, BCMA, and TACI - in various cancers, compared to their normal tissue or cell counterparts and in association with disease staging.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Databases
###end title 16
###begin p 17
###xml 45 47 45 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 104 157 104 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAFF, APRIL, BCMA, TACI, BAFF-R and HS proteoglycans </italic>
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 169 174 <span type="species:ncbi:9606">human</span>
We used Oncomine Cancer Microarray database [30] and Amazonia database [31] to study gene expression of BAFF, APRIL, BCMA, TACI, BAFF-R and HS proteoglycans genes in 40 human tumor types and their normal tissue counterparts as indicated in Table 1 (Additional file 1). Only gene expression data obtained from a single study using the same methodology were compared. All data were log transformed, median centred per array, and the standard deviation was normalized to one per array[32].
###end p 17
###begin title 18
Statistical analysis
###end title 18
###begin p 19
Statistical comparisons were done with Mann-Whitney or Student t-tests.
###end p 19
###begin title 20
Results and Discussion
###end title 20
###begin title 21
BAFF is overexpressed in solid tumors
###end title 21
###begin p 22
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 267 269 267 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 329 331 329 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 403 405 403 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 467 469 467 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 518 523 518 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAFF </italic>
###xml 580 582 580 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 593 595 593 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 603 605 603 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 618 620 618 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 633 635 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 645 646 645 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 711 720 711 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 750 755 750 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAFF </italic>
###xml 927 929 927 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1090 1095 1090 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAFF </italic>
###xml 1243 1245 1243 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1395 1400 1395 1400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAFF </italic>
###xml 1502 1504 1502 1504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1507 1509 1507 1509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1589 1591 1589 1591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1594 1596 1594 1596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1683 1685 1683 1685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1688 1690 1688 1690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1775 1777 1775 1777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1780 1782 1780 1782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 796 801 <span type="species:ncbi:9606">human</span>
40 tumor types were investigated, including 36 solid tumors and 4 hematological tumors (Additional file 1: Table 1). BAFF gene is overexpressed in 1/4 hematological tumors and in 5/36 solid tumors. BAFF is overexpressed in Hodgkin lymhoma compared to normal B cells (P = 4.9E-11), in Burkitt lymphoma compared to normal B cells (P = 5.4E-5), in diffuse large B cell lymphoma compared to normal B cells (P = .01) and in follicular lymphoma compared to normal B cells (P = 2E-6)[33]. Four independent studies have shown BAFF overexpression in glioblastoma compared to normal brain (P = 5.4E-13, P = 8E-6, P = 5.3E-5 and P = 0.008) [34-37] (Figure 1). Following stimulation with inflammatory cytokines, astrocytes in vitro produce high amounts of BAFF. BAFF is expressed in astrocytes in the normal human central nervous system and is strongly upregulated in activated astrocytes in the demyelinated lesions of multiple sclerosis[38]. BAFF secretion could be relevant in sustaining intrathecal B cell responses in autoimmune and infectious diseases of the central nervous system. Accordingly, BAFF expression is readily induced in the central nervous system by neurotrophic viruses and correlates with the recruitment of antibody-secreting cells[39]. The overexpression of BAFF in brain tumors could be linked to the accumulation of tumor cells or to inflammatory signals. Regarding other cancers, BAFF was found significantly overexpressed in breast carcinoma compared to normal breast (Richardson et al[40]; P = 2.4E-7), in esophageal adenocarcinoma compared to normal esophagus (Hao et al[41]; P = 3.7E-4), in clear cell renal cell carcinoma compared to normal kidney (Lenburg et al[42]; P = 2.1E-5) and in adult male germ cell tumor compared to normal testis (Korkola et al[43]; P = 8.3E-18).
###end p 22
###begin p 23
###xml 0 34 0 34 <bold xmlns:xlink="http://www.w3.org/1999/xlink">BAFF expression in various cancers</bold>
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAFF </italic>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
BAFF expression in various cancers. BAFF gene expression in normal brain, glioblastoma multiforme [34-37], normal breast, breast carcinoma[40], normal esophagus, esophageal adenocarcinoma[41], normal kidney, renal carcinoma[42], normal testis, adult male germ cell tumor[43], Hodgkin lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma and follicular lymphoma[33]. Data sets in a single panel were from the same study. GEP data are log transformed and normalized as previously described[32]. In brackets, are indicated the number of normal or tumor samples.
###end p 23
###begin title 24
APRIL is overexpressed in solid and hematological malignancies
###end title 24
###begin p 25
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APRIL </italic>
###xml 102 103 102 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 115 121 115 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APRIL </italic>
###xml 239 241 239 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 254 256 254 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 265 267 265 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 268 270 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 359 361 359 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 374 376 374 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 463 465 463 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 478 480 478 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 583 585 583 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 599 601 599 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 683 685 683 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 695 697 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 698 700 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 785 787 785 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 790 792 790 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 876 878 876 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 881 883 881 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 902 903 902 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
APRIL gene was overexpressed in 1/4 hematological and in 6/36 solid tumors in tumors (Additional file 1: Table 1). APRIL was overexpressed in invasive bladder carcinoma compared to superficial bladder carcinoma in two independent studies (P = 3.3E-6 and P = 0.003)[44,45], in esophageal adenocarcinoma compared to normal esophagus in two independent studies (P = 3.7E-4 and P = 5.5E-4)[41,46], in glioblastoma compared to normal brain in two independent studies (P = 3.5E-4 and P = 0.006)[34,36], in head and neck carcinoma compared to normal oral mucosa in two independent studies (P = 9.2E-10 and P = 0.009)[47,48], in diffuse large B cell lymphoma compared to normal lymph nodes (P = 7.6E-6)[49,50], in pancreatic adenocarcinoma compared to normal pancreas (Iocobuzio-Donahue et al[51]; P = 0.002) and in adult male germ cell tumor compared to normal testis (Korkola et al[43]; P = 1.6E-11) (Figure 2).
###end p 25
###begin p 26
###xml 0 35 0 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">APRIL expression in various cancers</bold>
###xml 96 98 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 378 380 378 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
APRIL expression in various cancers. APRIL gene expression in normal bladder, bladder carcinoma[44,45], normal esophagus, esophageal adenocarcinoma[41,46], normal brain, glioblastoma multiform[34,36], normal oral mucosa, head and neck carcinoma[47,48], normal B cell, lymphoma[49,50], normal pancreas, pancreatic adenocarcinoma[51], normal testis and adult male germ cell tumor[43]. Data sets in a single panel were from the same study. GEP data are log transformed and normalized as previously described[32]. In brackets, are indicated the number of normal or tumor samples.
###end p 26
###begin p 27
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 26 28 26 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APRIL </italic>
###xml 154 168 154 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAFF or APRIL </italic>
###xml 255 256 255 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 259 265 259 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APRIL </italic>
###xml 342 344 342 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 445 447 445 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 478 479 478 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 504 510 504 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APRIL </italic>
###xml 594 596 594 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 604 606 604 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 683 689 683 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APRIL </italic>
###xml 728 730 728 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 741 743 741 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 751 753 751 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 754 756 754 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 828 834 828 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APRIL </italic>
###xml 855 857 855 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 866 868 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 878 879 878 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 1022 1024 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1084 1086 1084 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 1116 1118 1116 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1420 1422 1420 1422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 1423 1425 1423 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 1523 1525 1523 1525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 1712 1714 1712 1714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 1941 1943 1941 1943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 2002 2008 2002 2008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APRIL </italic>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
###xml 418 426 <span type="species:ncbi:9606">patients</span>
###xml 530 538 <span type="species:ncbi:9606">patients</span>
###xml 567 575 <span type="species:ncbi:9606">patients</span>
###xml 1065 1070 <span type="species:ncbi:9606">human</span>
###xml 1907 1915 <span type="species:ncbi:9606">patients</span>
###xml 2011 2019 <span type="species:ncbi:9606">patients</span>
###xml 2091 2099 <span type="species:ncbi:9606">patients</span>
Recently, Schwaller et al[16] demonstrated that high APRIL expression in tumor lesions correlates with B-cell lymphoma aggressiveness. We found here that BAFF or APRIL expression could be also associated with tumor aggressiveness in other cancers (Figure 3). APRIL is significantly overexpressed in glioma grade 4 compared to glioma grade 3 (P = 3.1E-12) and in patients presenting glioma, dead at 3 years compared to patients alive at 3 years (P = 1.8E-4)[52] (Additional file 2). In bladder carcinoma, APRIL is overexpressed in patients dead at 3 years compared to patients alive at 3 years (P = .005)[53]. High tumor cell mass in breast cancer was also characterized by increased APRIL expression in two independent studies (P = .003 and P = .004)[54,55]. Stages II, III and IV cervical carcinoma showed an overexpression of APRIL compared to stage I (P = 0.003)[56] (Figure 3). On the contrary, BAFF overexpression was not associated with prognosis or tumor aggressiveness using online cancer gene expression analysis[32]. APRIL protein was detected in several human solid tumors[57] and normal epithelial cells[11]. Interestingly, APRIL protein expression was reported in larynx and oral cavity carcinoma, esophagus carcinoma, bladder carcinoma, breast cancer, pancreatic tumors, ovarian carcinoma, seminoma adenocarcinoma, glioblastoma multiforme and oligodendroglioma correlating with the results of our analysis[57,58]. In addition, neutrophils, present in the stroma of solid tumors, are major producers of APRIL [57] suggesting that APRIL overexpression may be due to infiltrating cells. Furthermore, APRIL that is produced in tumors is retained and accumulates in the tumor stroma though HSPG binding[57]. Nevertheless, an upregulation of APRIL protein (detected by in situ immunostaining) was shown to not alter disease-free and overall survivals of bladder, ovarian and head and neck carcinoma patients in retrospective studies[58]. We have identified here a significant overexpression of APRIL in patients with glioma or bladder carcinomas who were dead at 3 years compared to patients alive at 3 years. An explanation could be that a part of APRIL protein is quickly secreted and no more detectable by immunostaining. APRIL protein could also be used by tumor cells as a growth factor or released in the blood circulation.
###end p 27
###begin p 28
###xml 0 74 0 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Association between APRIL expression and aggressiveness in various cancers</bold>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
Association between APRIL expression and aggressiveness in various cancers. APRIL gene expression in glioma[52], bladder carcinoma[53], breast carcinoma[54,55] and cervical carcinoma[56]. Data sets in a single panel were from the same study. GEP data are log transformed and normalized as previously described[32]. In brackets, are indicated the number of normal or tumor samples.
###end p 28
###begin title 29
TACI is overexpressed in hematological cancers
###end title 29
###begin p 30
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCMA </italic>
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TACI </italic>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 217 222 217 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCMA </italic>
###xml 225 232 225 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAFF-R </italic>
###xml 392 397 392 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TACI </italic>
###xml 477 487 477 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Zhan et al</italic>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 493 495 493 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 559 570 559 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Huang et al</italic>
###xml 571 573 571 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 576 578 576 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 595 596 595 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 628 633 628 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TACI </italic>
###xml 858 860 858 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 863 865 863 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 882 883 882 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 740 748 <span type="species:ncbi:9606">patients</span>
###xml 817 825 <span type="species:ncbi:9606">patients</span>
We have previously reported the relevance of Affymetrix microarrays to quantify BCMA and TACI expressions in MM since microarray data were validated by real time RT-PCR and flow cytometry[20,21,59]. No differences in BCMA or BAFF-R expression between tumor cells and their normal counterparts could be found in the 40 cancer types available from Oncomine database. By contrast, a significant TACI overexpression was found in smoldering myeloma compared to normal plasma cells (Zhan et al[60]; P = 0.0009) and in thyroid carcinomas compared to normal thyroid (Huang et al[61]; P = 0.005) (Figure 4). Interestingly, we found that TACI expression is associated with a poor prognosis in Burkitt lymphoma. TACI is significantly overexpressed in patients presenting Burkitt lymphoma who were dead at five years compared to patients alive at five years (Dave et al[62]; P = 0.004) (Figure 4). Recently, it was described that APRIL-TACI interactions mediate non-Hodgkin lymphoma B-cell proliferation through Akt, regulating cyclin D1 and P21 expression[63]. These data suggest that TACI is the main receptor for BAFF/APRIL in lymphoma cells and is associated with a bad prognosis. TACI therefore represents a potential lymphoma therapeutic target.
###end p 30
###begin p 31
###xml 0 34 0 34 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TACI expression in various cancers</bold>
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TACI </italic>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
TACI expression in various cancers. TACI gene expression in normal plasma cells, smoldering myeloma[60], normal thyroid, thyroid carcinoma[61] and lymphoma[62]. Data sets in a single panel were from the same study. GEP data are log transformed and normalized as previously described[32]. In brackets, are indicated the number of normal or tumor samples.
###end p 31
###begin title 32
Correlations between APRIL and heparan sulfate chain proteoglycans overexpression in tumor cells
###end title 32
###begin p 33
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 219 225 219 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 238 244 238 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">at al </italic>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 646 648 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
Receptors for BAFF and APRIL are expressed exclusively by lymphoid cells. APRIL can bind and promote tumor-cell proliferation of several cell lines that do not express detectable mRNA for TACI and BCMA[9,64,65]. Ingold et al and Hendriks at al identified proteoglycans as the APRIL-non specific binding partners. This binding is mediated by HS side chains and can be inhibited by heparin[26,27]. Only APRIL expression was associated with a bad prognosis in several cancers. APRIL could sustain the survival of malignant cells directly through HS proteoglycans that can deliver signals through their intracellular tails upon binding to ligands[66,67].
###end p 33
###begin p 34
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 225 226 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 496 502 496 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APRIL </italic>
###xml 567 568 567 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
Eleven HS proteoglycans has been identified so far - syndecan 1-4, glypican 1-6, CD44 isoforms containing the alternatively spliced exon v3 - and their gene expression can be evaluated by microarrays[68] (see Additional file 3). Interestingly, at least one HS proteoglycan gene was significantly overexpressed in cancers presenting an overexpression of APRIL compared to their normal counterparts (see Additional file 1). A similar observation was made for cancers showing an association between APRIL expression and the evolution of the disease (see Additional file 1).
###end p 34
###begin p 35
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
HS proteoglycans regulate growth factor signaling, cytoskeleton organization, cell adhesion and migration[69]. HS proteoglycans are implicated in solid tumor development[70,71]. Syndecan-1 is absolutely required for the development of mammary tumors driven by the transgenic expression of the proto-oncogene Wnt-1 in mice[72]. The important role of HS proteoglycans is attributed in part to its highly negative electric potential, making it able to bind numerous proteins and to function as a coreceptor. However as APRIL activates cells that do not express TACI or BCMA, a direct signaling by the HS proteoglycans core protein is possible as already shown [66]. It may explain the overexpression of APRIL in association with disease aggressiveness in solid tumors which do not express BCMA or TACI. Nevertheless, additional studies are required to understand the exact role of APRIL in solid tumors, the existence of a signaling linked to the interaction of APRIL with HS proteoglycans and the possible existence of a receptor specific to APRIL not yet identified.
###end p 35
###begin title 36
Conclusion
###end title 36
###begin p 37
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APRIL </italic>
###xml 890 892 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 295 303 <span type="species:ncbi:9606">patients</span>
###xml 812 820 <span type="species:ncbi:9606">patients</span>
The analysis reported here demonstrates that APRIL mRNA is overexpressed in at least 8 cancers compared to their normal counterparts, and within a given tumor category, is associated with a bad prognosis. These observations emphasize the interest using BAFF/APRIL inhibitors in the treatment of patients with cancers. We recently completed a phase I-II clinical trial of Atacicept TACI-Fc inhibitor showing the feasibility and safety of this targeting in multiple myeloma (submitted data). Heparin could be also useful in blocking APRIL binding to surface HS proteoglycan. Of note, we found here always one HS proteoglycan gene overexpressed in tumors that also highly expressed APRIL. A recent study reported that a brief course of subcutaneous low molecular weight heparin favorably influences the survival in patients with advanced malignancy and deserves additional clinical evaluation[73]. Thus, the targeting of APRIL or its interaction with HS proteoglycans may be promising in a large number of cancers.
###end p 37
###begin title 38
Competing interests
###end title 38
###begin p 39
The authors declare that they have no competing interests.
###end p 39
###begin title 40
Authors' contributions
###end title 40
###begin p 41
JM designed research, performed the analyses and wrote the paper. JLV and JDV have been involved in drafting and reviewing of the manuscript. BK is the senior investigator who designed research and wrote the paper. All authors read and approved the final manuscript.
###end p 41
###begin title 42
Pre-publication history
###end title 42
###begin p 43
The pre-publication history for this paper can be accessed here:
###end p 43
###begin p 44

###end p 44
###begin title 45
Supplementary Material
###end title 45
###begin title 46
Additional file 1
###end title 46
###begin p 47
###xml 14 40 14 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAFF, APRIL, TACI, BAFF-R </italic>
###xml 44 74 44 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">heparan sulfate proteoglycans </italic>
###xml 0 236 0 236 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of <italic>BAFF, APRIL, TACI, BAFF-R </italic>and <italic>heparan sulfate proteoglycans </italic>in human tumor types to that of their normal tissue counterparts using publicly available gene expression data, including the Oncomine Cancer Microarray database.</bold>
###xml 77 82 <span type="species:ncbi:9606">human</span>
Expression of BAFF, APRIL, TACI, BAFF-R and heparan sulfate proteoglycans in human tumor types to that of their normal tissue counterparts using publicly available gene expression data, including the Oncomine Cancer Microarray database.
###end p 47
###begin p 48
Click here for file
###end p 48
###begin title 49
Additional file 2
###end title 49
###begin p 50
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Classification of cancers included in the analysis.</bold>
Classification of cancers included in the analysis.
###end p 50
###begin p 51
Click here for file
###end p 51
###begin title 52
Additional file 3
###end title 52
###begin p 53
###xml 0 379 0 379 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Gene expression profile of Syndecan 1&#8211;4 and glypican 1&#8211;6 was determined using Oncomine Cancer Microarray database in bladder carcinoma, esophagus adenocarcinoma, brain tumors, breast cancer, head and neck tumors, lymphoma, pancreatic adenocarcinoma and adult male germ cell tumors presenting an overexpression of APRIL or an association with a bad prognosis or tumor progression.</bold>
Gene expression profile of Syndecan 1-4 and glypican 1-6 was determined using Oncomine Cancer Microarray database in bladder carcinoma, esophagus adenocarcinoma, brain tumors, breast cancer, head and neck tumors, lymphoma, pancreatic adenocarcinoma and adult male germ cell tumors presenting an overexpression of APRIL or an association with a bad prognosis or tumor progression.
###end p 53
###begin p 54
Click here for file
###end p 54
###begin title 55
Acknowledgements
###end title 55
###begin p 56
This work was supported by grants from the Ligue Nationale Contre le Cancer (equipe labellisee 2006), Paris, France, from INCA (ndegreesR07001FN) and from MSCNET European strep (NdegreesE06005FF).
###end p 56
###begin article-title 57
Synthesis and release of B-lymphocyte stimulator from myeloid cells
###end article-title 57
###begin article-title 58
BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth
###end article-title 58
###begin article-title 59
Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase
###end article-title 59
###begin article-title 60
TWE-PRIL; a fusion protein of TWEAK and APRIL
###end article-title 60
###begin article-title 61
An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein
###end article-title 61
###begin article-title 62
###xml 70 75 <span type="species:ncbi:9606">human</span>
BAFF selectively enhances the survival of plasmablasts generated from human memory B cells
###end article-title 62
###begin article-title 63
TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts
###end article-title 63
###begin article-title 64
BAFF AND APRIL: A Tutorial on B Cell Survival
###end article-title 64
###begin article-title 65
APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth
###end article-title 65
###begin article-title 66
APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early life bone marrow stromal cells
###end article-title 66
###begin article-title 67
###xml 101 106 <span type="species:ncbi:9606">human</span>
APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa
###end article-title 67
###begin article-title 68
BLyS and BLyS receptor expression in non-Hodgkin's lymphoma
###end article-title 68
###begin article-title 69
Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas
###end article-title 69
###begin article-title 70
Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL
###end article-title 70
###begin article-title 71
###xml 107 114 <span type="species:ncbi:9606">Patient</span>
Expression of BLyS and Its Receptors in B-Cell Non-Hodgkin Lymphoma: Correlation With Disease Activity and Patient Outcome
###end article-title 71
###begin article-title 72
###xml 88 93 <span type="species:ncbi:9606">human</span>
Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness
###end article-title 72
###begin article-title 73
Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL
###end article-title 73
###begin article-title 74
Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway
###end article-title 74
###begin article-title 75
Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival
###end article-title 75
###begin article-title 76
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
###end article-title 76
###begin article-title 77
###xml 106 111 <span type="species:ncbi:9606">human</span>
TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines
###end article-title 77
###begin article-title 78
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone
###end article-title 78
###begin article-title 79
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
###end article-title 79
###begin article-title 80
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts
###end article-title 80
###begin article-title 81
B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia
###end article-title 81
###begin article-title 82
Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation
###end article-title 82
###begin article-title 83
Identification of proteoglycans as the APRIL-specific binding partners
###end article-title 83
###begin article-title 84
A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth
###end article-title 84
###begin article-title 85
Selective activation of TACI by syndecan-2
###end article-title 85
###begin article-title 86
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression
###end article-title 86
###begin article-title 87
###xml 19 24 <span type="species:ncbi:9606">human</span>
A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas
###end article-title 87
###begin article-title 88
ONCOMINE: a cancer microarray database and integrated data-mining platform
###end article-title 88
###begin article-title 89
Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis
###end article-title 89
###begin article-title 90
###xml 113 118 <span type="species:ncbi:9606">human</span>
Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas
###end article-title 90
###begin article-title 91
Gene expression profiles associated with treatment response in oligodendrogliomas
###end article-title 91
###begin article-title 92
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain
###end article-title 92
###begin article-title 93
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme
###end article-title 93
###begin article-title 94
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma
###end article-title 94
###begin article-title 95
CNS viral infection diverts homing of antibody-secreting cells from lymphoid organs to the CNS
###end article-title 95
###begin article-title 96
###xml 42 47 <span type="species:ncbi:9606">human</span>
X chromosomal abnormalities in basal-like human breast cancer
###end article-title 96
###begin article-title 97
Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma
###end article-title 97
###begin article-title 98
Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data
###end article-title 98
###begin article-title 99
###xml 136 141 <span type="species:ncbi:9606">human</span>
Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors
###end article-title 99
###begin article-title 100
Bladder cancer outcome and subtype classification by gene expression
###end article-title 100
###begin article-title 101
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays
###end article-title 101
###begin article-title 102
Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation
###end article-title 102
###begin article-title 103
Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck
###end article-title 103
###begin article-title 104
Association between gene expression profile and tumor invasion in oral squamous cell carcinoma
###end article-title 104
###begin article-title 105
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
###end article-title 105
###begin article-title 106
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
###end article-title 106
###begin article-title 107
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays
###end article-title 107
###begin article-title 108
Gene expression profiling of gliomas strongly predicts survival
###end article-title 108
###begin article-title 109
Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles
###end article-title 109
###begin article-title 110
Identification of molecular apocrine breast tumours by microarray analysis
###end article-title 110
###begin article-title 111
Prognosis and gene expression profiling of 20q13-amplified breast cancers
###end article-title 111
###begin article-title 112
Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity
###end article-title 112
###begin article-title 113
###xml 37 42 <span type="species:ncbi:9606">human</span>
The source of APRIL up-regulation in human solid tumor lesions
###end article-title 113
###begin article-title 114
Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas
###end article-title 114
###begin article-title 115
Binding of TACI and APRIL to Syndecan-1 Confer on Them a Major Role in Multiple Myeloma
###end article-title 115
###begin article-title 116
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
###end article-title 116
###begin article-title 117
Gene expression in papillary thyroid carcinoma reveals highly consistent profiles
###end article-title 117
###begin article-title 118
Molecular diagnosis of Burkitt's lymphoma
###end article-title 118
###begin article-title 119
APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21
###end article-title 119
###begin article-title 120
###xml 78 83 <span type="species:ncbi:9606">human</span>
Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor
###end article-title 120
###begin article-title 121
Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization
###end article-title 121
###begin article-title 122
Syndecans: proteoglycan regulators of cell-surface microdomains?
###end article-title 122
###begin article-title 123
Glypicans in growth control and cancer
###end article-title 123
###begin article-title 124
Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma
###end article-title 124
###begin article-title 125
Functions of cell surface heparan sulfate proteoglycans
###end article-title 125
###begin article-title 126
Roles of heparan-sulphate glycosaminoglycans in cancer
###end article-title 126
###begin article-title 127
Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer
###end article-title 127
###begin article-title 128
###xml 66 70 <span type="species:ncbi:10090">mice</span>
Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice
###end article-title 128
###begin article-title 129
###xml 58 66 <span type="species:ncbi:9606">patients</span>
The effect of low molecular weight heparin on survival in patients with advanced malignancy
###end article-title 129

